News

Dengue fever – a 30% breakthrough
Enlarge image

BusinessFrance

Dengue fever – a 30% breakthrough

13.09.2012 - Sanofi-Pasteur has suffered a setback with its dengue fever vaccine. It proved to be far less effective than originally hoped. But this is not the end of the story.

Results from a Phase IIb study conducted in Thailand revealed the vaccine had about 30% overall efficacy against dengue fever type 2. Originally, the French pharma hoped to achieve more than 70% efficacy. The compound did show strong results against types 1, 3 and 4 of the mosquito-borne disease. However patients with a type 2 infection, the most prevalent strain in Thailand at the time of the study, did not show a satisfactory response. The vaccine candidate is meant to protect against all four types viruses that cause dengue. The result leaves uncertainty on the future of a product that Sanofi estimates it could generate more than €1bn in annual sales. Sanofi has invested €350m in a site to manufacture the vaccine. Still, the vaccine shows promise and Phase III studies involving more than 31,000 children and adults are under way in 10 countries across Asia and Latin America.

Dengue fever, a mosquito-borne disease, also known as "breakbone fever", is a threat to nearly 3 billion people in tropical regions. "This result knocked me off my chair," Scott Halstead, a senior scientific adviser for the non-profit Dengue Vaccine Initiative, who was not involved in the study, told Reuters. Sanofi had already published topline data in July saying that the study had shown efficacy against three of the four strains. However, the company did not present any details. The full findings were published online in the The Lancet. If the Thai trial results had been as strong as expected, Sanofi could have filed for early approval in some countries. Instead, Sanofi now has to wait for the phase III results. A commercial launch can now happen in 2015 or later.

© eurobiotechnews.eu/pd

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M&AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M&ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

M&AFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

BioeconomyBelgiumUK

30.06.2014 Building on a £1.2m financing round, Celtic Renewables partners with a Belgian pilot plant to bring its bio-fuel made from whisky production residue to an industrial scale.

ConventionEUUK

25.06.2014 Sun, celebrities and a scandal - the world’s largest biotech convention is getting off to an explosive start in San Diego, California.

InvestmentGermanyNetherlands

24.06.2014 Bayer Healthcare is getting back into gene therapy with a US$252m deal aimed at the development of a haemophilia A treatment.

InvestmentNetherlands

20.06.2014 Tomtom founder Pieter Geelen invests in Dutch biotech Ocello, the company behind a 3D mapping technology used for predicting drug behaviour in patients.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • FLAMEL TECHNOLOGIES (F)14.70 USD11.28%
  • SERODUS (N)3.05 NOK7.02%
  • ADDEX (CH)4.54 CHF5.83%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.48 EUR-10.04%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.43 EUR102.0%

FLOP

  • THROMBOGENICS (B)8.67 EUR-51.3%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.67 EUR-73.1%

No liability assumed, Date: 11.07.2014